

Subject Step Therapy Prohibition for Metastatic Cancer

Authors Cantrell and others

Analyst Randall Chun

Date March 29, 2019

Overview

This bill prohibits the use of step therapy protocols when treating stage four advanced metastatic cancer, if the drug to be used for treatment meets specified criteria.

Summary

Section	Description
1	<p>Prohibition on use of step therapy for metastatic cancer.</p> <p>Adds § 62Q.1841.</p> <p>Subd. 1. Definitions. Defines the following terms: health plan, stage four metastatic cancer, and step therapy protocol.</p> <p>Subd. 2. Prohibition on use of step therapy protocols. Prohibits a health plan that provides coverage for the treatment of stage four advanced metastatic cancer or associated conditions from limiting or excluding coverage for a drug approved by the Food and Drug Administration (FDA) that is on the plan's formulary, by mandating that the enrollees follow a step therapy protocol, if the use of the approved drug is consistent with: (1) a FDA-approved indication; and (2) a clinical practice guideline published by the National Comprehensive Care Network.</p> <p>States that the section is effective January 1, 2020, and applies to health plans offered, issued, or renewed on or after that date.</p>
2	<p>Prior authorization.</p> <p>Amends § 256B.0625, subd. 13f. Requires any step therapy protocol requirements established by the Commissioner of Human Services to comply with section 62Q.1841. Provides a January 1, 2020, effective date.</p>



Minnesota House Research Department provides nonpartisan legislative, legal, and information services to the Minnesota House of Representatives. This document can be made available in alternative formats.

www.house.mn/hrd | 651-296-6753 | 600 State Office Building | St. Paul, MN 55155